Over the past several decades, messenger RNA (mRNA) vaccines have progressed from a
scepticism-inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the�…

Mucosal vaccines offer the potential to trigger robust protective immune responses at the
predominant sites of pathogen infection. In principle, the induction of adaptive immunity at�…

Background Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract
infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV�…

Background The safety of the monoclonal antibody nirsevimab and the effect of nirsevimab
on hospitalizations for respiratory syncytial virus (RSV)–associated lower respiratory tract�…

Background Lower respiratory infections are a leading cause of morbidity and mortality
around the world. The Global Burden of Diseases, Injuries, and Risk Factors (GBD) Study�…

Viruses that replicate in the human respiratory mucosa without infecting systemically,
including influenza A, SARS-CoV-2, endemic coronaviruses, RSV, and many other"�…

Background Assessments of age-specific mortality and life expectancy have been done by
the UN Population Division, Department of Economics and Social Affairs (UNPOP), the�…

As of May 6, 2020, nearly 3� 7 million people have been infected and around 260 000
people have died from coronavirus disease 2019 (COVID-19) worldwide. 1 Almost all�…

The world is facing Coronavirus Disease-2019 (COVID-19) pandemic, which is causing a
large number of deaths and burden on intensive care facilities. It is caused by Severe Acute�…

Since the beginning of the COVID-19 pandemic, reduced incidence of many viral and
bacterial infections has been reported in children: bronchiolitis, varicella, measles, pertussis�…